{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:30:22Z","timestamp":1790069422410,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81721002"],"award-info":[{"award-number":["81721002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573676"],"award-info":[{"award-number":["81573676"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81371852"],"award-info":[{"award-number":["81371852"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671399"],"award-info":[{"award-number":["81671399"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National 13th Five-Year Special Grand Project for Infectious Diseases","award":["2017ZX10302201-001"],"award-info":[{"award-number":["2017ZX10302201-001"]}]},{"name":"Dongguan International Science & Technology Cooperation","award":["201650812001"],"award-info":[{"award-number":["201650812001"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.antiviral.2019.02.012","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T06:30:07Z","timestamp":1550730607000},"page":"131-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Prevalence of the entecavir-resistance-inducing mutation rtA186T in a large cohort of Chinese hepatitis B virus patients"],"prefix":"10.1016","volume":"164","author":[{"given":"Lujie","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinguang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.02.012_bib1","first-page":"2159","article-title":"Guideline on prevention and treatment of chronic hepatitis B in China (2005)","volume":"120","year":"2007","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.antiviral.2019.02.012_bib2","first-page":"13","article-title":"The guideline of prevention and treatment for chronic hepatitis B (2010 version)","volume":"19","year":"2011","journal-title":"Zhonghua Gan Zang Bing Za Zhi (Chin. J. Hepatol.)"},{"key":"10.1016\/j.antiviral.2019.02.012_bib4","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/hep.21422","article-title":"Entecavir resistance is rare in nucleoside naive patients with hepatitis B","volume":"44","author":"Colonno","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.02.012_bib5","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3851\/IMP2928","article-title":"Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine","volume":"20","author":"Geipel","year":"2015","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2019.02.012_bib6","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jhep.2015.03.020","article-title":"Characterization of novel entecavir resistance mutations","volume":"63","author":"Hayashi","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2019.02.012_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.14218\/JCTH.2016.00019","article-title":"Guideline of prevention and treatment for chronic hepatitis B (2015 Update)","volume":"5","author":"Hou","year":"2017","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.antiviral.2019.02.012_bib8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcv.2012.02.003","article-title":"The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation","volume":"54","author":"Ji","year":"2012","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2019.02.012_bib9","doi-asserted-by":"crossref","first-page":"10874","DOI":"10.3748\/wjg.v21.i38.10874","article-title":"Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies","volume":"21","author":"Kim","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2019.02.012_bib10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2019.02.012_bib11","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1128\/JCM.01518-10","article-title":"Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients","volume":"48","author":"Li","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2019.02.012_bib12","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/gutjnl-2014-308353","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial","volume":"65","author":"Lim","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2019.02.012_bib13","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/jvh.12298","article-title":"The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil","volume":"22","author":"Liu","year":"2015","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2019.02.012_bib14","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3851\/IMP2775","article-title":"Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients","volume":"19","author":"Liu","year":"2014","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2019.02.012_bib15","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3851\/IMP1679","article-title":"Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B","volume":"15","author":"Liu","year":"2010","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2019.02.012_bib16","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/j.1365-2893.2010.01360.x","article-title":"Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection","volume":"18","author":"Liu","year":"2011","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2019.02.012_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3851\/IMP2971","article-title":"Increased occurrence of mutant rtI233V of HBV in patients receiving adefovir therapy","volume":"21","author":"Liu","year":"2016","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2019.02.012_bib18","article-title":"rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.02.012_bib19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.02.012_bib20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/hep.21698","article-title":"Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management","volume":"46","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.02.012_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2014.04.005","article-title":"Nucleoside\/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance","volume":"8","author":"Men\u00e9ndez-Arias","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2019.02.012_bib22","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jhep.2017.07.011","article-title":"How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?","volume":"67","author":"Rajoriya","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2019.02.012_bib23","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/hep4.1231","article-title":"Discovery of the novel entecavir-resistant hepatitis B virus reverse transcriptase A181C substitution from an integrated genotypic analysis","volume":"2","author":"Rose","year":"2018","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.antiviral.2019.02.012_bib24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2893.2012.01638.x","article-title":"Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen","volume":"20","author":"Svarovskaia","year":"2013","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2019.02.012_bib25","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic hepatitis B infection: a review","volume":"319","author":"Tang","year":"2018","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.antiviral.2019.02.012_bib26","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.02.012_bib27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1053\/j.gastro.2008.09.068","article-title":"In vitro characterization of viral fitness of therapy-resistant hepatitis B variants","volume":"136","author":"Villet","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.02.012_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009195","article-title":"Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir","volume":"5","author":"Walsh","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.02.012_bib31","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2002.34740","article-title":"Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks","volume":"36","author":"Yang","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.02.012_bib32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virusres.2018.07.021","article-title":"Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient","volume":"255","author":"Zhang","year":"2018","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2019.02.012_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.antiviral.2018.04.003","article-title":"Hepatitis B virus rtA181T\/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T\/sW172* mutation","volume":"154","author":"Zhao","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.02.012_bib34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2006-939759","article-title":"In vitro models for studying hepatitis B virus drug resistance","volume":"26","author":"Zoulim","year":"2006","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.antiviral.2019.02.012_bib35","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.02.012_bib36","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/gutjnl-2011-300937","article-title":"Reasons to consider earlier treatment of chronic HBV infections","volume":"61","author":"Zoulim","year":"2012","journal-title":"Gut"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218306673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218306673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T13:37:30Z","timestamp":1565185050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218306673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":33,"alternative-id":["S0166354218306673"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.02.012","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of the entecavir-resistance-inducing mutation rtA186T in a large cohort of Chinese hepatitis B virus patients","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}